GlassScriptPhysician profile
Randolph Dean Lizardo
NPI 1104026756
$5,434.54
in general payments reported to CMS, 2019-2025
42 companies · $769 in 2025
The $769 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $447 · 2021: $846 · 2022: $918 · 2023: $952 · 2024: $808 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,407.40 | 2019-2023 | |
| Pfizer INC. | $533.72 | 2019-2024 | |
| Davol INC. | $409.18 | 2025 | Arista |
| Sumitomo Pharma America, INC. | $371.35 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $346.62 | 2020-2025 | Veozah |
| Medtronic, INC. | $229.00 | 2024-2025 | Sonicision, Symplicity G3 |
| Meditrina | $214.42 | 2022-2025 | |
| Caldera Medical, INC | $200.27 | 2024 | Desara |
| Daiichi Sankyo INC. | $162.32 | 2019-2025 | Injectafer |
| Coopersurgical, INC. | $156.69 | 2019-2025 | Mara Console, Paragard T 380a, Paragard T 380a |
| Myovant Sciences INC. | $153.64 | 2021-2022 | |
| Duchesnay USA Incorporated | $118.68 | 2019 | |
| Mayne Pharma Commercial LLC | $113.02 | 2021-2025 | |
| Millicent US INC | $87.94 | 2019-2024 | Intrarosa, Femring |
| Avion Pharmaceuticals | $83.53 | 2021-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $82.42 | 2019-2020 | |
| Therapeuticsmd, INC. | $66.33 | 2020 | |
| Amgen INC. | $55.58 | 2022-2023 | Evenity, Prolia |
| Steris Corporation | $53.25 | 2020-2021 | |
| Exeltis, USA INC. | $52.81 | 2023-2024 | Slynd |
| Axonics, INC. | $46.52 | 2024 | Axonics |
| Trevena, INC. | $45.44 | 2023 | Olinvyk |
| Evofem Biosciences, INC. | $43.74 | 2021-2022 | |
| Agile Therapeutics, INC. | $38.02 | 2022-2024 | Twirla |
| Exact Sciences Corporation | $37.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aspira Women'S Health INC | $36.37 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $33.08 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $29.01 | 2019 | |
| Shield Therapeutics INC | $23.26 | 2025 | |
| Abbott Laboratories | $20.29 | 2019 | |
| Distalmotion US | $20.25 | 2025 | Dexter L6 Robot |
| Glaxosmithkline, LLC. | $19.96 | 2019 | |
| Merck Sharp & Dohme LLC | $17.85 | 2019 | |
| Hologic Sales and Service, LLC | $17.51 | 2025 | Novasure, Myosure Tissue Removal Device |
| Ferring Pharmaceuticals INC. | $16.84 | 2019 | |
| Sage Therapeutics, LLC | $16.31 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $16.31 | 2025 | Qelbree |
| Seqirus USA INC | $15.36 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Vertical Pharmaceuticals, LLC | $14.86 | 2019 | |
| Mission Pharmacal Company | $14.77 | 2019 | |
| Channel Medsystems, INC. | $12.96 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Lizardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.